Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheterization, Swan-Ganz | 1 | 2016 | 13 | 0.480 |
Why?
|
| Vascular System Injuries | 1 | 2016 | 23 | 0.470 |
Why?
|
| Aneurysm, False | 1 | 2016 | 47 | 0.470 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 96 | 0.450 |
Why?
|
| Heart Failure | 4 | 2018 | 965 | 0.400 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2011 | 2 | 0.350 |
Why?
|
| Vasopressins | 1 | 2011 | 15 | 0.350 |
Why?
|
| Hyponatremia | 1 | 2011 | 11 | 0.350 |
Why?
|
| Hospital Mortality | 3 | 2026 | 879 | 0.230 |
Why?
|
| Amyloidosis | 1 | 2026 | 70 | 0.230 |
Why?
|
| Cardiac Myosins | 1 | 2025 | 25 | 0.220 |
Why?
|
| Uracil | 1 | 2025 | 36 | 0.220 |
Why?
|
| Hospitalization | 2 | 2026 | 1403 | 0.220 |
Why?
|
| Benzylamines | 1 | 2025 | 35 | 0.220 |
Why?
|
| Cardiomyopathies | 1 | 2026 | 137 | 0.210 |
Why?
|
| Inpatients | 1 | 2026 | 322 | 0.200 |
Why?
|
| Sepsis | 1 | 2026 | 302 | 0.180 |
Why?
|
| Rupture | 1 | 2016 | 24 | 0.120 |
Why?
|
| Fluoroscopy | 1 | 2016 | 69 | 0.120 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2025 | 801 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 143 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 348 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 196 | 0.100 |
Why?
|
| Acute Disease | 2 | 2016 | 663 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 409 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 337 | 0.090 |
Why?
|
| Vasoconstriction | 1 | 2011 | 22 | 0.090 |
Why?
|
| Aged | 6 | 2026 | 15089 | 0.090 |
Why?
|
| Benzazepines | 1 | 2011 | 21 | 0.090 |
Why?
|
| Pyrroles | 1 | 2011 | 50 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 69 | 0.080 |
Why?
|
| Prognosis | 2 | 2016 | 1791 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2011 | 107 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2011 | 252 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 462 | 0.070 |
Why?
|
| Humans | 8 | 2026 | 65645 | 0.060 |
Why?
|
| Risk Factors | 3 | 2026 | 5466 | 0.060 |
Why?
|
| Female | 6 | 2026 | 34309 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2005 | 27 | 0.060 |
Why?
|
| Aminophylline | 1 | 2005 | 4 | 0.060 |
Why?
|
| Urea | 1 | 2025 | 42 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 54 | 0.050 |
Why?
|
| Bradycardia | 1 | 2005 | 33 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 170 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2005 | 246 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 199 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2018 | 2113 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 1715 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2005 | 263 | 0.050 |
Why?
|
| Middle Aged | 5 | 2026 | 18439 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 809 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 555 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5820 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 3777 | 0.040 |
Why?
|
| United States | 2 | 2026 | 8166 | 0.040 |
Why?
|
| Male | 5 | 2026 | 31292 | 0.030 |
Why?
|
| Data Warehousing | 1 | 2018 | 7 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5656 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2016 | 11 | 0.030 |
Why?
|
| Data Mining | 1 | 2016 | 38 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 149 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 294 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 309 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2026 | 6948 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1116 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 21459 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 888 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2016 | 398 | 0.020 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2005 | 3 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 40 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 25 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 27 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 2005 | 21 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 170 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 328 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 296 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 193 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2005 | 212 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 558 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 858 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1144 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2496 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 921 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 3329 | 0.010 |
Why?
|
| Adult | 1 | 2005 | 17511 | 0.000 |
Why?
|